Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study of Debio 025 (Alisporivir) Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 Patients

This study has been completed.
Sponsor:
Collaborator:
Parexel
Information provided by (Responsible Party):
Debiopharm International SA
ClinicalTrials.gov Identifier:
NCT00854802
First received: March 2, 2009
Last updated: January 13, 2015
Last verified: January 2015
  Purpose

The purpose of this study is to compare several Debio 025 (alisporivir)/peg-IFNα2a/ribavirin triple therapies with the current standard of care (SOC) in treatment naïve chronic hepatitis C genotype 1 patients.


Condition Intervention
Chronic Hepatitis C
Drug: Debio 025
Drug: Peg-IFNα2a
Drug: Ribavirin
Drug: Debio 025 placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicentre, Randomised, Double-blind, Placebo-controlled, Parallel-group Phase II Study on the Efficacy and Safety of Debio 025 Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 Patients

Resource links provided by NLM:


Further study details as provided by Debiopharm International SA:

Primary Outcome Measures:
  • Percentage of participants achieving sustained viral response (SVR) 72 weeks after treatment start [ Time Frame: 72 weeks after treatment start ] [ Designated as safety issue: No ]
    SVR is defined as hepatitis C virus (HCV) RNA < 10 IU/mL (undetectable).


Secondary Outcome Measures:
  • Percentage of participants achieving a rapid viral response (RVR) after 4 weeks of treatment [ Time Frame: 4 weeks after treatment start ] [ Designated as safety issue: No ]
    RVR is defined as HCV RNA level < 10 IU/mL after 4 weeks of treatment.

  • Percentage of participants achieving a complete early viral response (cEVR) after 12 weeks of treatment [ Time Frame: 12 weeks after treatment start ] [ Designated as safety issue: No ]
    cEVR is defined as HCV RNA level < 10 IU/mL after 12 weeks of treatment.

  • Percentage of participants achieving an early viral response (EVR) after 12 weeks of treatment [ Time Frame: 12 weeks after treatment start ] [ Designated as safety issue: No ]
    EVR is defined as a decrease from baseline of the HCV RNA level by > 2 log10 or undetectable (< 10 UI/mL) after 12 weeks of treatment.

  • Percentage of participants achieving an end-of-treatment response (ETR) at treatment end [ Time Frame: at end of treatment (Week 28 or Week 52) ] [ Designated as safety issue: No ]
    ETR is defined as HCV RNA level < 10 IU/mL at the end of treatment (Week 24 or Week 48).

  • Percentage of participants achieving a sustained viral response 12 weeks after the end of treatment (SVR 12) [ Time Frame: 12 weeks after end of treatment (Week 40 or Week 64) ] [ Designated as safety issue: No ]
    SVR 12 is defined as HCV RNA level < 10 IU/mL 12 weeks after the end of treatment (Week 40 or Week 64).

  • Percentage of participants with sustained viral response 24 weeks after the end of treatment (SVR 24) [ Time Frame: 24 weeks after end of treatment (Week 52 or Week 76 ] [ Designated as safety issue: No ]
    SVR 24 is defined as HCV RNA level < 10 IU/mL 24 weeks after the end of treatment (Week 52 or Week 76).


Enrollment: 290
Study Start Date: January 2009
Study Completion Date: September 2010
Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Debio 025 600 mg + peg-IFNα2a + ribavirin - 48 weeks
Participants receive Debio 025 600 mg orally twice daily for 7 days (loading dose) followed by Debio 025 600 mg orally once daily for 47 weeks + peg-IFNα2a 180 µg subcutaneously (sc) once weekly for 48 weeks + ribavirin 1000 or 1200 mg (weight based) orally daily for 48 weeks.
Drug: Debio 025
Debio 025 supplied in soft gel capsules
Other Name: Alisporivir
Drug: Peg-IFNα2a
Peg-IFNα2a supplied in pre-filled syringes
Other Name: Pegasys
Drug: Ribavirin
Ribavirin supplied in tablets
Other Names:
  • Copegus
  • Rebetol
  • Ribasphere
  • Vilona
  • Virazole
Experimental: Debio 025 600 mg + peg-IFNα2a + ribavirin - 24 weeks
Participants receive Debio 025 600 mg orally twice daily for 7 days (loading dose) followed by Debio 025 600 mg orally once daily for 23 weeks + peg-IFNα2a 180 µg sc once weekly for 24 weeks + ribavirin 1000 or 1200 mg (weight based) orally daily for 24 weeks.
Drug: Debio 025
Debio 025 supplied in soft gel capsules
Other Name: Alisporivir
Drug: Peg-IFNα2a
Peg-IFNα2a supplied in pre-filled syringes
Other Name: Pegasys
Drug: Ribavirin
Ribavirin supplied in tablets
Other Names:
  • Copegus
  • Rebetol
  • Ribasphere
  • Vilona
  • Virazole
Experimental: Debio 025 600 mg + peg-IFNα2a + ribavirin - 24 or 48 weeks
Participants receive Debio 025 600 mg orally twice daily for 7 days (loading dose) followed by Debio 025 600 mg orally once daily for 23 or 47 weeks + peg-IFNα2a 180 µg sc once weekly for 24 or 48 weeks + ribavirin 1000 or 1200 mg (weight based) orally daily for 24 or 48 weeks. Participants who achieve a rapid viral response, defined as having undetectable hepatitis C virus RNA at week 4, are treated for 24 weeks; other patients are treated for 48 weeks.
Drug: Debio 025
Debio 025 supplied in soft gel capsules
Other Name: Alisporivir
Drug: Peg-IFNα2a
Peg-IFNα2a supplied in pre-filled syringes
Other Name: Pegasys
Drug: Ribavirin
Ribavirin supplied in tablets
Other Names:
  • Copegus
  • Rebetol
  • Ribasphere
  • Vilona
  • Virazole
Placebo Comparator: Debio 025 placebo + peg-IFNα2a + ribavirin - 48 weeks
Participants receive Debio 025 placebo orally twice daily for 7 days followed by Debio 025 placebo orally once daily for 47 weeks + peg-IFNα2a 180 µg subcutaneously (sc) once weekly for 48 weeks + ribavirin 1000 or 1200 mg (weight based) orally daily for 48 weeks.
Drug: Peg-IFNα2a
Peg-IFNα2a supplied in pre-filled syringes
Other Name: Pegasys
Drug: Ribavirin
Ribavirin supplied in tablets
Other Names:
  • Copegus
  • Rebetol
  • Ribasphere
  • Vilona
  • Virazole
Drug: Debio 025 placebo
Debio 025 placebo supplied in soft gel capsules

Detailed Description:

This is an international, multicentre, randomised, double-blind, placebo-controlled, 4-arm, parallel-group, multiple dose phase II study comparing 3 Debio 025 (alisporivir)/peg-IFNα2a/ribavirin regimens to SOC treatment in treatment naïve chronic HCV genotype 1 patients.

Patients are randomised into 1 of 4 arms receiving either Debio 025/peg-IFNα2a/ribavirin triple therapy for a fixed treatment duration of 48 weeks (Treatment A) or 24 weeks (Treatment B), Debio 025/peg-IFNα2a/ribavirin triple therapy for a response-based treatment duration of 24 or 48 weeks (Treatment C), or blinded SOC treatment for 48 weeks (Treatment D). Follow-up is 24 weeks in all treatment arms.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Males or females aged ≥ 18 and ≤ 65 years.
  • Body mass index (BMI) ≥ 18 and ≤ 32 kg/m^2.
  • Hepatitis B surface antigen (HbsAg) negative and HIV-1 negative.
  • Serological diagnosis of chronic hepatitis C viral infection genotype 1 for > 6 months.
  • Chronic liver disease consistent with chronic hepatitis C infection on a biopsy or FibroScan® obtained within the past 24 months (36 months for patients with incomplete/transition to cirrhosis).
  • Previously untreated for hepatitis C virus (HCV) infection (approved or investigational drug).
  • Plasma HCV RNA level lower limit ≥ 100 IU/ml assessed by quantitative polymerase chain reaction (qPCR) or equivalent; no upper limit.
  • Neutrophil count ≥ 1500/µL; hemoglobin (Hb) ≥ 12g/dL for females and ≥ 13g/dL for males; platelets ≥ 90,000/µL.
  • Patients with incomplete/transition to cirrhosis on biopsy or an elasticity score between 9.5 and 14 kPa on FibroScan must have an abdominal ultrasound (US), computed tomographic (CT) scan, or magnetic resonance imaging (MRI) scan without evidence of hepatocellular carcinoma (within 2 months prior to randomisation) and a serum alpha-foetoprotein (AFP) < 100 ng/mL.
  • Aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT) < 5 times the upper limit of normal.
  • Normal or compensated liver function and absence of complicated portal hypertension as documented by the following:

    • No history of bleeding oesophageal varices;
    • Absence of ascites;
    • Absence of encephalopathy;
    • Albumin ≥ 35 g/L;
    • Total bilirubin ≤ 1.8 mg/dL (≤ 30 µmol/L);
    • Prothrombin (INR ≤ 1.5).
  • Creatinine clearance > 50 mL/min.
  • Thyroid stimulating hormone (TSH) within normal range;
  • All patients should be informed about Debio 025 and ribavirin foetotoxicity:

    • Females may participate if they are surgically sterile or post-menopausal. Pre-menopausal females may participate if they use 2 reliable contraceptive methods (oral contraceptive + barrier method). The contraceptive regimen must be maintained during the treatment period and for 4 months after the last Debio 025 or ribavirin dose.
    • Male patients must be surgically sterile or use 2 reliable contraceptive methods (oral contraceptive + barrier method). The contraceptive regimen must be maintained during the treatment period and for 7 months after the last Debio 025 or ribavirin dose.
  • Signed informed consent before any study procedures.
  • Negative pregnancy test within one week of first investigational product administration for female patients of child bearing potential.

Exclusion Criteria:

  • Treatment with any investigational drug within 6 months prior to the first dose of investigational product.
  • HCV genotype different from genotype 1.
  • Any previous HCV treatment (approved or investigational).
  • Histologic evidence of complete hepatic cirrhosis (including compensated cirrhosis) based on a previous liver biopsy (if available).
  • Ongoing or recent use of any other medication (including over the counter medication and herbal products) within 2 weeks before study start or within 5 drug half-lives of that medication (whichever is longer) that are known inhibitors/inducers of cytochrome P450 (CYP450) 3A, substrates of P-glycoprotein 1 (P-gP), or substrates/inhibitors of organic anion-transporting polypeptides (OATP), multidrug resistance-associated protein 2 (MRP2), or bile salt export pump (BSEP) and are mentioned in the list of unauthorised medications;
  • Any medical contraindications to peg-IFNα2a and/or ribavirin treatment;
  • Any other cause of relevant liver disease other than HCV including but not limited to hepatitis B virus (HBV), drug- or alcohol-related cirrhosis, autoimmune hepatitis, haemochromatosis, Wilson's disease, nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), or primary biliary cirrhosis (PBC).
  • Any other condition which, in the opinion of the Investigator, would make the patient unsuitable for enrollment or could interfere with the patient participating in and completing the study. Patients with risk factors (hypertension or diabetes) need to have an ophthalmologic investigation (including fundoscopy).
  • History of moderate, severe, or uncontrolled psychiatric disease, especially depression, including a history of hospitalisation or prior suicidal attempt.
  • Uncontrolled arterial hypertension, ie, patients with systolic BP ≥ 160 mmHg and/or diastolic BP ≥ 100 mmHg.
  • History of pancreatitis, uncontrolled diabetes mellitus, or retinopathy.
  • Anti-nuclear antibody (ANA) titre > 1:640 at screening and/or evidence of autoimmune hepatitis on liver biopsy.
  • Alcohol consumption > 20 g/day for females and > 30 g/day for males.
  • History of major organ transplantation with an existing functional graft.
  • Pregnancy or lactation.
  • Haemoglobinopathies (thalassaemia major, sickle cell anaemia or drepanocytosis).
  • Familial history of severe neonatal cholestasis or pregnancy cholestasis.
  • Evidence of an active or suspected cancer, or a history of malignancy where the risk of recurrence is ≥ 20% within 2 years.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00854802

  Show 40 Study Locations
Sponsors and Collaborators
Debiopharm International SA
Parexel
Investigators
Study Director: Rafael Crabbé, MD Debiopharm International SA
  More Information

Additional Information:
Publications:

Responsible Party: Debiopharm International SA
ClinicalTrials.gov Identifier: NCT00854802     History of Changes
Other Study ID Numbers: Debio 025-HCV-205, 2008-004605-34
Study First Received: March 2, 2009
Last Updated: January 13, 2015
Health Authority: Belgium: Federal Agency for Medicinal Products and Health Products
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Germany: Federal Institute for Drugs and Medical Devices
Italy: The Italian Medicines Agency
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Romania: National Medicines Agency
Spain: Spanish Agency of Medicines

Keywords provided by Debiopharm International SA:
Hepatitis
Hepatitis C

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis C
Hepatitis C, Chronic
Hepatitis, Chronic
Digestive System Diseases
Enterovirus Infections
Flaviviridae Infections
Hepatitis, Viral, Human
Liver Diseases
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Interferon-alpha
Peginterferon alfa-2a
Ribavirin
Anti-Infective Agents
Antimetabolites
Antiviral Agents
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on March 02, 2015